Limb perfusion, hyperthermic

Author:Prof. Dr. med. Peter Altmeyer

All authors of this article

Last updated on: 29.10.2020

Dieser Artikel auf Deutsch

Requires free registration (medical professionals only)

Please login to access all articles, images, and functions.

Our content is available exclusively to medical professionals. If you have already registered, please login. If you haven't, you can register for free (medical professionals only).


Requires free registration (medical professionals only)

Please complete your registration to access all articles and images.

To gain access, you must complete your registration. You either haven't confirmed your e-mail address or we still need proof that you are a member of the medical profession.

Finish your registration now

DefinitionThis section has been translated automatically.

Perfusion of a limb with cytostatic drugs under hyperthermia (39-40 °C). Use in malignant melanoma with multiple satellites and/or in transit metastases. Remission rates are given as 50-80%. The use as adjuvant therapy is still under review. The therapeutic procedure is only used in special centres.

ImplementationThis section has been translated automatically.

Representation of the peripheral vessels of the affected extremity. Insertion of catheters into the main vein and artery (e.g. arteria and vena femoralis) and creation of an extracorporeal circulation with pump oxygenator. Decoupling the limb circulation from the body circulation by applying a tourniquet in the groin. Heating of the blood to the desired temperature and addition of the cytostatic drug. Perfusion over one hour, longer perfusion time increases the complication rate. Common cytostatic drugs are melphalan (alkeran) and cisplatin (e.g. Cisplatin Lsg. medac). In some centres, good success was shown with the perfusion of tumour necrosis factor in combination with melphalan, which was superior to the therapy with melphalan alone (level of evidence IIB).

Undesirable effectsThis section has been translated automatically.

NW, both systemic (e.g. hair loss, leakage problem, leukocyte loss) and local (damage to the arteries, veins and lymphatic vessels), can be expected in some patients.

LiteratureThis section has been translated automatically.

  1. Barth A et al (1995) The role of adjuvant therapy in melanoma management. Cancer 75: 726-734
  2. Cornett WR et al (2006) Randomized multicenter trial of hyperthermic isolated limb perfusion with melphalan alone compared with melphalan plus tumor necrosis factor: American College of Surgeons Oncology Group trial Z0020. J Clin Oncol 24: 4196-4201
  3. Koller J et al (1995) Hyperthermic limb perfusion with melphalan loco-regional melanoma metastases. Z Hautkr 70: 271-274
  4. Krementz ET AL et al (1995) Regional chemotherapy for melanoma - a 35-year. Annals of Surgery 220: 520-535
  5. Schlag PM et al (1995) Isolated limb perfusion with tumor necrosis factor and melphalan. dermatologist 46: 361-362

Authors

Last updated on: 29.10.2020